Abivax Shares Dive Over 30% Following Safety Concerns in Phase 3 Trial

Abivax SA's stock took a nosedive, dropping more than 30% after the company revealed findings from its Phase 3 ABTECT trial on obefazimod. The drug hit efficacy targets, with remission rates hovering around 40% for both dosages tested, but the trial also flagged cancer cases among patients on the higher dose.

While Abivax maintains that these cancer occurrences were deemed unrelated to the treatment and lacked any organ-specific pattern, the market clearly wasn't buying the reassurance. The news pushed the stock to €78.60, marking a significant retreat from recent levels.

Adding fuel to the fire, Jefferies downgraded Abivax from Buy to Hold, slashing their price target from $160 to $90. Their analysts flagged the cancer findings as a complicating factor that could weigh on the stock, especially given the lack of other major catalysts on the horizon.

Not everyone jumped ship. Morgan Stanley kept its Overweight rating but trimmed the target price to $132. Similarly, Truist Securities and Citizens Financial held onto their positive stances while adjusting targets-ranging from $135 to an optimistic $187-showing there's still some belief in the company's prospects despite the setback.

From a broader viewpoint, Abivax's plunge was an island of negativity on a day when major US indexes edged up modestly: the S&P 500 increased by 0.3%, Nasdaq rose 0.4%, and the Dow Jones added 0.1%. No wider biotech sector downturn triggered the selloff, pointing to the company-specific nature of the drop.

Abivax also dropped its Q1 2026 financials, highlighting a solid cash pile of €491.6 million, enough to keep the lights on through at least late 2027. While that's a cushion in tough times, it wasn't enough to stem investor worries over the safety concerns indicated by the trial.

The company is planning to file a New Drug Application with the FDA for obefazimod in ulcerative colitis in the fourth quarter of 2026. Whether regulators will take the same view as the trial investigators on the cancer cases remains a big question mark hanging over the stock's near-term outlook.

With several analysts taking varied positions and investor sentiment shifting on safety signals, Abivax faces a tricky path forward. The market's reaction is a reminder of how volatile biotech stocks can be when unexpected data clouds the picture.